By Dr. Gabriela Lenarczyk Dr. Lenarczyk is a 2024-2025 Edison Fellow. This blog post is in partial fulfillment of obligations for the Thomas Edison Innovation Law and Policy Fellowship. Recently resurfaced […]
IPPI Cautions that Pharmaceutical Tariffs Would Harm Patients and U.S. Innovation Leadership
IPPI has submitted formal comments to the U.S. Department of Commerce regarding its Section 232 investigation of pharmaceutical imports, cautioning against imposing tariffs on medicines and their ingredients. In our […]
[Archived Post] What the FTC Gets Wrong About the FDA’s Orange Book
By Emily Michiko Morris & Douglas Park The high cost of some pharmaceuticals is a complex issue, but the Federal Trade Commission’s (FTC’s) most recent criticism of pharmaceutical patents’ role […]
Pharmaceutical “Nominal Patent Life” Versus “Effective Patent Life,” Revisited
By Emily Michiko Morris and Joshua Kresh Executive summary: Many critics of pharmaceutical companies argue that they abuse the patent system through “evergreening” or “thickets” to increase the amount of […]
[Archived Post] Professors Erika Lietzan and Kristina Acri Argue That Current Data Do Not Support Evergreening Allegations
By Jack Ring In their forthcoming paper, Solutions Still Searching for a Problem: A Call for Relevant Data to Support “Evergreening” Allegations,[1] C-IP2 Senior Scholars Erika Lietzan of Mizzou Law […]
[Archived Post] C-IP2 Statement on Interactions between Courts and the FDA
Courts have recently questioned Food and Drug Administration (FDA) determinations. The FDA is the administrative agency whose job is to evaluate scientific data to determine if a drug is safe […]
[Archived Post] Policy Brief: The TRIPS Waiver for COVID-19 Vaccines, and Its Potential Expansion: Assessing the Impact on Global IP Protection and Public Health
This policy brief, including the following “Introduction and Executive Summary,” comes from Eric M. Solovy. CLICK HERE to read the brief in full. Introduction and Executive Summary On June 17, […]
[Archived Post] Reply and Response to C-IP2’s March 4, 2021, Blogpost on UC Hastings’ Evergreen Drug Patent Search Database
C-IP2’s original post on the UC Hastings’ Evergreen Drug Patent Search Database can be read here. Reply to Blog Post on UC Hastings’ Evergreen Drug Patent Search Database Robin Feldman […]
[Archived Post] UC Hastings’ Evergreen Drug Patent Search Database: A Look Behind the Statistics Reveals Problems with this Approach to Identifying and Quantifying So-Called “Evergreening”
Professor Robin Feldman’s reply to this post, and our response, can be read read here. The Center for Innovation, housed at the University of California Hastings College of the Law, has […]
[Archived Post] Professors Erika Lietzan and Kristina Acri on “Distorted Drug Patents”
The following post comes from Austin Shaffer, a 2L at Scalia Law and a Research Assistant at CPIP. By Austin Shaffer In their new paper, Distorted Drug Patents, CPIP Senior […]